Baseline patient characteristics in the whole data set
| Patient characteristics (n; %) . | BV cohort (n = 386) . | Chemotherapy cohort (n = 382) . | P value . |
|---|---|---|---|
| Female sex | 202 (52%) | 168 (44%) | .021 |
| Age, y, median (range) | 31 (5-68) | 34 (18-72) | .031 |
| WHO PS | < .001 | ||
| 0 | 158 (64%) | 256 (70%) | .1030 |
| 1 | 85 (34%) | 79 (22%) | .0008 |
| 2 | 5 (2%) | 29 (8%) | .0029 |
| Unknown | 138 | 18 | |
| Ann Arbor stage | < .001 | ||
| I | 29 (9%) | 43 (11%) | .3589 |
| II | 132 (41%) | 135 (36%) | .1861 |
| III | 53 (16%) | 59 (16%) | .8534 |
| II or III∗ | 0 (0%) | 24 (6%) | NA |
| IV | 109 (34%) | 117 (31%) | .4791 |
| Unknown | 63 | 4 | |
| B symptoms | 107 (28%) | 74 (23%) | .133 |
| Unknown | 2 | 59 | |
| Extranodal disease | 142 (38%) | 134 (35%) | .493 |
| Unknown | 8 | 1 | |
| Bulky disease† | 128 (37%) | 101 (31%) | .126 |
| Unknown | 40 | 60 | |
| Primary refractory‡ | 213 (55%) | 78 (20%) | < .001 |
| Relapse interval in days, median (range) | 147 (0-4883) | 250 (0-5258) | .123 |
| Unknown | 212 | 6 | |
| Early relapse <1 year | 259 (76%) | 230 (61%) | < .001 |
| Unknown | 43 | 5 | |
| Response to primary treatment | < .001 | ||
| Complete response | 173 (59%) | 304 (89%) | < .001 |
| Partial response | 55 (19%) | 21 (6%) | < .001 |
| Stable disease | 18 (6%) | 2 (1%) | < .001 |
| Progressive disease | 46 (16%) | 14 (4%) | < .001 |
| Unknown | 94 | 41 | |
| Primary treatment | < .001 | ||
| ABVD | 254 (90%) | 259 (71%) | < .001 |
| BEACOPP | 16 (6%) | 79 (22%) | < .001 |
| Other | 11 (4%) | 25 (7%) | .1455 |
| Unknown | 105 | 19 | |
| BV maintenance after ASCT | 87 (24%) | NA | NA |
| Patient characteristics (n; %) . | BV cohort (n = 386) . | Chemotherapy cohort (n = 382) . | P value . |
|---|---|---|---|
| Female sex | 202 (52%) | 168 (44%) | .021 |
| Age, y, median (range) | 31 (5-68) | 34 (18-72) | .031 |
| WHO PS | < .001 | ||
| 0 | 158 (64%) | 256 (70%) | .1030 |
| 1 | 85 (34%) | 79 (22%) | .0008 |
| 2 | 5 (2%) | 29 (8%) | .0029 |
| Unknown | 138 | 18 | |
| Ann Arbor stage | < .001 | ||
| I | 29 (9%) | 43 (11%) | .3589 |
| II | 132 (41%) | 135 (36%) | .1861 |
| III | 53 (16%) | 59 (16%) | .8534 |
| II or III∗ | 0 (0%) | 24 (6%) | NA |
| IV | 109 (34%) | 117 (31%) | .4791 |
| Unknown | 63 | 4 | |
| B symptoms | 107 (28%) | 74 (23%) | .133 |
| Unknown | 2 | 59 | |
| Extranodal disease | 142 (38%) | 134 (35%) | .493 |
| Unknown | 8 | 1 | |
| Bulky disease† | 128 (37%) | 101 (31%) | .126 |
| Unknown | 40 | 60 | |
| Primary refractory‡ | 213 (55%) | 78 (20%) | < .001 |
| Relapse interval in days, median (range) | 147 (0-4883) | 250 (0-5258) | .123 |
| Unknown | 212 | 6 | |
| Early relapse <1 year | 259 (76%) | 230 (61%) | < .001 |
| Unknown | 43 | 5 | |
| Response to primary treatment | < .001 | ||
| Complete response | 173 (59%) | 304 (89%) | < .001 |
| Partial response | 55 (19%) | 21 (6%) | < .001 |
| Stable disease | 18 (6%) | 2 (1%) | < .001 |
| Progressive disease | 46 (16%) | 14 (4%) | < .001 |
| Unknown | 94 | 41 | |
| Primary treatment | < .001 | ||
| ABVD | 254 (90%) | 259 (71%) | < .001 |
| BEACOPP | 16 (6%) | 79 (22%) | < .001 |
| Other | 11 (4%) | 25 (7%) | .1455 |
| Unknown | 105 | 19 | |
| BV maintenance after ASCT | 87 (24%) | NA | NA |
Patient characteristics are measured at time of enrollment in the studies, that is, at time of relapse or primary refractory disease, unless indicated otherwise.
NA, not applicable; WHO PS, World Health Organization performance status.
For 24 patients in the chemotherapy cohort from the trial by Santoro et al, stage at relapse was not recorded but stage I and IV were deducted from the amount of involved lymph node sites, extranodal sites, and bone marrow involvement. It was not possible to distinguish between stage II and III disease because no data were available on the spatial distribution of nodal sites (ie, infradiaphragmatic and/or supradiaphragmatic location).
Bulky disease was defined as a single tumor bulk larger than 5 cm.
Primary refractory disease was defined as not having achieved a CR on primary treatment, ie, patients who had a PR, SD, or progressive disease (PD) on primary treatment were considered primary refractory independent of the relapse interval.